Analysts Set Replimune Group, Inc. (NASDAQ:REPL) PT at $19.43

Replimune Group, Inc. (NASDAQ:REPL) has been assigned a consensus recommendation of “Buy” from the eight ratings firms that are currently covering the firm, Marketbeat reports. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $19.43.

A number of brokerages have recently commented on REPL. HC Wainwright boosted their price objective on Replimune Group from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. Jefferies Financial Group boosted their price objective on Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, December 4th. BMO Capital Markets boosted their target price on Replimune Group from $18.00 to $27.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 22nd. Finally, JPMorgan Chase & Co. boosted their target price on Replimune Group from $16.00 to $18.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th.

Hedge Funds Weigh In On Replimune Group

A number of large investors have recently modified their holdings of REPL. Baker BROS. Advisors LP grew its stake in shares of Replimune Group by 10.0% in the third quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company’s stock valued at $121,057,000 after buying an additional 1,000,000 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Replimune Group by 11.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 10,962,883 shares of the company’s stock valued at $132,761,000 after buying an additional 1,083,633 shares in the last quarter. Redmile Group LLC grew its stake in shares of Replimune Group by 2.6% in the fourth quarter. Redmile Group LLC now owns 4,905,527 shares of the company’s stock valued at $59,406,000 after buying an additional 124,344 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Replimune Group by 3.7% in the fourth quarter. Vanguard Group Inc. now owns 3,595,848 shares of the company’s stock valued at $43,546,000 after buying an additional 129,601 shares in the last quarter. Finally, Braidwell LP grew its stake in shares of Replimune Group by 203.0% in the third quarter. Braidwell LP now owns 3,070,837 shares of the company’s stock valued at $33,656,000 after buying an additional 2,057,460 shares in the last quarter. 92.53% of the stock is currently owned by hedge funds and other institutional investors.

Replimune Group Stock Up 0.6 %

Shares of REPL opened at $11.50 on Monday. The firm has a market cap of $885.67 million, a P/E ratio of -3.75 and a beta of 1.30. Replimune Group has a 12-month low of $4.92 and a 12-month high of $17.00. The company’s 50-day moving average price is $12.66 and its 200 day moving average price is $12.13. The company has a current ratio of 11.43, a quick ratio of 11.43 and a debt-to-equity ratio of 0.14.

Replimune Group (NASDAQ:REPL) last released its earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.09). On average, sell-side analysts forecast that Replimune Group will post -2.97 earnings per share for the current year.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.